Mechanical thrombectomy for acute ischemic stroke in COVID-19 patients: multicenter experience in 111 cases

Hanna Styczen,1 Volker Maus,2 Lukas Goertz,3 Martin Köhrmann,4 Christoph Kleinschnitz,4 Sebastian Fischer,2 Markus Möhlenbruch,5 Iris Mühlen,6 Bernd Kallmünzer,7 Franziska Dorn,8 Asadeh Lakghomi,8 Matthias Gawlitza,9 Daniel Kaiser,9 Joachim Klisch,10 Donald Lobsien,10 Stefan Rohde,11 Gisa Ellrichmann,12 Daniel Behme,13 Maximilian Thomann,14 Fabian Flottmann,15 Laurens Winkelmeier,15 Elke R Gizewski,16 Lukas Mayer-Suess,17 Tobias Boecht-Behrens,18 Isabelle Riederer,18 Randolf Klingebiel,19 Björn Berger,19 Martin Schluenz-Hendann,20 Dominik Grieb,20 Ali Khanafé,21 Richard du Mesnil de Rochemont,22 Christophe Arendt,22 Jens Altenbernd,23 Jan-Ulrich Schlump,24 Adrian Ringelstein,25 Vivian Jean Marcel Sanio,25 Christian Loehr,26 Agnes Maria Dahlke,26 Carolin Brockmann,27 Sebastian Reder,27 Ulrich Sure,28 Yan Li,1 Ruben Mühl-Benninghaus,29 Thomas Rott,29 Kai Kallenberg,30 Alexandru Durutya,30 Mohamed Elsharkawy,31 Paul Stracke,31 Mathias Gerhard Schumann,32 Alexander Bock,32 Omid Nikoubashman,33 Martin Wiesmann,33 Hans Henkes,31 Pascal J Mosimann,34 René Chapot,34 Michael Forsting,1 Cornelius Deuschl1

ABSTRACT

Background Data on the frequency and outcome of mechanical thrombectomy (MT) for large vessel occlusion (LVO) in patients with COVID-19 is limited. Addressing this subject, we report our multicenter experience.

Methods A retrospective cohort study was performed of consecutive acute stroke patients with COVID-19 infection treated with MT at 26 tertiary care centers between January 2020 and November 2021. Baseline demographics, angiographic outcome and clinical outcome evaluated by the modified Rankin Scale (mRS) at discharge and 90 days were noted.

Results We identified 111 out of 11,365 (1%) patients with acute or subinsid COVID-19 infection who underwent MT due to LVO. Cardioembolic events were the most common etiology for LVO (38.7%). Median baseline National Institutes of Health Stroke Scale score and Alberta Stroke Program Early CT Score were 16 (IQR 11.5–20) and 9 (IQR 7–10), respectively. Successful reperfusion (mTICI ≥2b) was achieved in 97/111 (87.4%) patients and 46/111 (41.4%) patients were reperfused completely. The procedure-related complication rate was 12.6% (14/111). Functional independence was achieved in 20/108 (18.5%) patients at discharge and 14/66 (21.2%) at 90 days follow-up. The in-hospital mortality rate was 30.6% (33/108). In the subgroup analysis, patients with severe acute COVID-19 infection requiring intubation had a mortality rate twice as high as patients with mild or moderate acute COVID-19 infection. Acute respiratory failure requiring ventilation and time interval from symptom onset to groin puncture were independent predictors for an unfavorable outcome in a logistic regression analysis.

Conclusion Our study showed a poor clinical outcome and high mortality, especially in patients with severe acute COVID-19 infection undergoing MT due to LVO.

BACKGROUND

Neurological complications during infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are common, ranging from 25% to 80% of patients hospitalized with COVID-19.1,2 A clear association of acute cerebrovascular disease with COVID-19 has been observed, with an overall pooled incidence of 1.4% in a recent meta-analysis.3 Acute ischemic stroke (AIS) is the most common manifestation of acute cerebrovascular disease in patients suffering from COVID-19 and is reported as a presenting feature of the young.4,5,6 Compared with the pre-pandemic period, younger patients with COVID-19 without vascular risk factors have been undergoing mechanical thrombectomy (MT) for AIS due to large vessel occlusion (LVO).7,8 Studies suggest that the activation of the coagulation pathway is related to the infection-induced systemic inflammatory response.7 SARS-CoV-2 enters the blood stream by breaching the blood–air barrier via the lung capillary adjacent to the alveolus. As the blood–air barrier is breached, a cascade of events unfolds including endothelial...
The pandemic and neurointervention
dysfunction, formation of antiphospholipid antibody complexes promoting platelet aggregation, coagulation cascade, and formation of cross-linked fibrin blood clots, leading to thrombosis and stroke in individuals with COVID-19 infection.8

Due to the systemic effect of the coronavirus with hypercoagulation, hyperinflammation and respiratory insufficiency, a poor prognosis and increased mortality among COVID-19 patients treated by MT for LVO must be assumed.9 Specific characteristics of COVID-19-associated stroke still remain unknown, and data on the frequency and outcome of patients with COVID-19 undergoing MT for AIS are limited.10,11

We aimed to report our multicenter experience with MT in patients with AIS and associated COVID-19 infection, evaluating the angiographic and clinical outcome.

METHODS
We conducted a retrospective study of patients with AIS with laboratory-confirmed acute or subsided (within 6 months) COVID-19 infection who were treated endovascularly at 26 tertiary care centers in Germany and Austria between January 2020 and November 2021. We identified all patients who received MT or were treated with the intention for thrombectomy due to LVO in cerebral arteries including the distal internal carotid artery, middle cerebral artery (M1, M2 and M3), anterior cerebral artery (A1 and A2), distal vertebral artery, basilar artery, and posterior cerebral artery (P1 and P2). A confirmed diagnosis of COVID-19 was defined by a positive laboratory result for SARS-CoV-2 on high-throughput sequencing or reverse transcription PCR assay of nasal and/or oropharyngeal swab specimens.

Demographics, comorbidities, technical features, complications, angiographic and clinical outcomes were noted. The etiology of the occlusion was based on the TOAST classification. There were no limitations on procedural characteristics including the use of different thrombectomy techniques and intra-arterial thrombolysis, which were left to the attending neuroradiologist’s discretion. Endovascular treatment was performed with approved MT devices, using stent-retrievers or large-bore aspiration catheters or a combination of both.

Complete reperfusion was defined as a modified Thrombolysis in Cerebral Infarction (mTICI) scale score of 3. Successful reperfusion was defined as mTICI 2b. The clinical efficacy outcome was the rate of functional independence measured by the modified Rankin Scale (mRS) and defined as 0–2 at discharge and 90 days. All National Institutes of Health Stroke Scale (NIHSS) and mRS grades were assessed by a consultant neurologist. Post-interventional symptomatic intracranial hemorrhage (sICH) was graded according to the European Cooperative Acute Stroke Study criteria.11

According to the guidelines of the respective local ethics committees, ethical approval was given when necessary for this anonymous retrospective study, which was conducted in accordance with the Declaration of Helsinki. Patient consent for treatment was obtained according to the individual institutional guidelines. Due to the retrospective nature of the study, additional informed consent was deemed unnecessary.

Statistical analysis
Categorical variables are presented as numbers and percentages and compared using the χ² and Fisher’s exact test, as appropriate. Ordinal variables are presented as median with SD and compared using the Student’s t-test and Mann–Whitney U test, as appropriate. Factors predictive of an unfavorable outcome (mRS 3–6) at discharge in the univariate analysis (p<0.05) were entered into a binary logistic stepwise regression model to identify independent factors for an unfavorable outcome. Independent variables included in the logistic regression analyses were tested for multicollinearity calculating the variance inflation factor (VIF). A VIF >5 was assumed to indicate high multicollinearity between the respective independent variable and the others. In this case, strongly correlating variables were identified and stepwise eliminated until all independent variables had a VIF ≤5. All calculations were performed using SPSS software version 25 (IBM SPSS Statistics for Windows, IBM Corp, Armonk, New York, USA). A p value <0.05 was considered statistically significant.

RESULTS
Of 11,365 patients from 26 tertiary stroke centers screened, 111 patients with acute or subsided COVID-19 infection underwent MT due to LVO between January 2020 and November 2021. The prevalence of MT in COVID-19 patients measured by the case volume of all centers during the inclusion time was 1%

Baseline characteristics
Out of 111 patients, 97 patients had a laboratory-confirmed diagnosis of acute COVID-19 infection and 14 patients presented after subsided COVID-19 infection. The acute COVID-19 infection was determined during hospitalization, immediately before or after the endovascular thrombectomy, with a reverse transcription PCR test. Patient baseline characteristics are shown in table 1.

Of 97 patients with acute COVID-19 infection, 31 (32%) presented with a severe course requiring intubation due to acute respiratory failure during hospitalization. Mild (without respiratory distress) and moderate (requiring non-invasive ventilation) courses of COVID-19 infection were found in 43 (44.3%) and 23 (23.7%) patients, respectively. The median age was 74 (IQR 63–82) years and 70/111 (63.1%) were male. Seven patients (6.3%) were younger than 50 years.

LVO was localized in the anterior circulation in 101/111 (91%) patients, with most common sites in M1 (51/101; 50.5%) and distal internal carotid artery (25/101; 24.8%), followed by A1 and A2 (21/101; 20.8%). Basilar artery occlusion represented 9% of cases.

Tandem occlusion occurred in 19/111 (17.1%) patients. In 5/111 (4.5%) cases re-occlusion within 30 days was observed. Of these, three cases of large vessel re-occlusion were localized in the same territory and in two cases a different territory was affected. Intravenous thrombolysis (IVT) was administered in 48/111 (43.2%) patients.

Median baseline NIHSS and ASPECTS were 16 (IQR 11.5–20) and 9 (IQR 7–10), respectively.

The median interval between onset and groin puncture was 220 (IQR 150–290) min. Thirty-nine (35.1%) patients presented as wake-up strokes. The rate of pretreatment functional independence (mRS ≤2) was 73% (81/111).

Cardioembolic cause was the most common etiology for LVO and was found in 43/111 (38.7%) patients, followed by large artery atherosclerosis (22/111; 19.8%). In 11/111 (9.9%) patients other etiology (eg, dissection, infectious) was found. Stroke etiology remained unknown in 34/111 (30.6%) patients.

Procedural and functional outcome
MT was performed under general anesthesia in 100/111 (90.1%) and conscious sedation in 11/111 (9.9%) patients. The median

2 of 6
Styczyn H, et al. J NeuroIntervent Surg 2022;14:858–862. doi:10.1136/neurintsurg-2022-018723

http://jnis.bmj.com/ J NeuroIntervent Surg: first published as 10.1136/neurintsurg-2022-018723 on 15 March 2022. Downloaded from http://jnis.bmj.com/ on December 12, 2022 by guest. Protected by copyright.
Spontaneous recanalization occurred in three cases and in two
patients first-pass complete reperfusion (mTICI 3) was performed.

The most common first-pass technique was a combined approach with aspiration and stent-
retriever thrombectomy in 58/111 (52.3%) patients, followed
by aspiration thrombectomy in 46/111 (41.4%) patients. In one
patient first-line stent-retriever thrombectomy was performed.

Successful reperfusion was achieved in 97/111 (87.4%) patients
and 46/111 (41.4%) patients were reperfused completely. The
procedure-related complication rate was 12.6% (14/111). sICH occurred in 6/111 (5.4%) patients. Of these, one patient
presented with additional subarachnoid hemorrhage (SAH) and another with iatrogenic intra-arterial
dissection. Since the dissection was localized extracranially in the internal carotid
artery without hemodynamic relevance, no further treatment was required. Of six patients with sICH, parenchymal hema-
toma (PH) was found in three cases (2 cases of PH-1 and 1 case of PH-2) and hemorrhagic infarction (HI) was found in three
cases (2 cases of HI-1 and 1 case of HI-2). In total, nine patients
presented with SAH (8.1%).

Functional independence was achieved in 20/108 (18.5%) patients at discharge and 14/66 (21.2%) at 90 days follow-up.
The mortality rate was 30.6% (33/108) at discharge and 56.1% (37/66) at 90 days follow-up. Clinical outcome at discharge and
at 90 days was not documented in 3 and 45 patients, respectively.

Clinical outcome of the seven patients under the age of 50
years with COVID-19 infection showed an increased likelihood of functional independence (at discharge)
compared with patients with acute COVID-19 infection (mRS 0–2: 5/14 (35.7%) vs 15/94 (15.5%), p=0.076). In addition, the
mortality rate at discharge was lower in patients recovered from
COVID-19 compared with patients with acute COVID-19 infection,
but without statistical significance (mRS 6: 2/14 (14.3%) vs
31/94 (33%), p=0.16).

time interval from groin to final reperfusion was 44 (IQR 28–69) min and the median number of thrombectomy
maneuvers was 2 (IQR 1–3) (Table 2). The most common first-pass technique was a combined approach with aspiration and stent-
retriever thrombectomy in 58/111 (52.3%) patients, followed
by aspiration thrombectomy in 46/111 (41.4%) patients. In one
patient first-line stent-retriever thrombectomy was performed.
Spontaneous recanalization occurred in three cases and in two
cases the thrombus localization could not be reached. One
patient with intention to MT presented with ventricular fibril-
bation at the beginning of the endovascular procedure and died eventually of pulmonary artery embolism.

Successful reperfusion was achieved in 97/111 (87.4%) patients
and 46/111 (41.4%) patients were reperfused completely. The
procedure-related complication rate was 12.6% (14/111). sICH occurred in 6/111 (5.4%) patients. Of these, one patient
presented with additional subarachnoid hemorrhage (SAH) and another with iatrogenic intra-arterial
dissection. Since the dissection was localized extracranially in the internal carotid
artery without hemodynamic relevance, no further treatment was required. Of six patients with sICH, parenchymal hema-
toma (PH) was found in three cases (2 cases of PH-1 and 1 case of PH-2) and hemorrhagic infarction (HI) was found in three
cases (2 cases of HI-1 and 1 case of HI-2). In total, nine patients
presented with SAH (8.1%).

Functional independence was achieved in 20/108 (18.5%) patients at discharge and 14/66 (21.2%) at 90 days follow-up.
The mortality rate was 30.6% (33/108) at discharge and 56.1% (37/66) at 90 days follow-up. Clinical outcome at discharge and
at 90 days was not documented in 3 and 45 patients, respectively.

Clinical outcome of the seven patients under the age of 50
years with COVID-19 infection showed an increased likelihood of functional independence (at discharge)
compared with patients with acute COVID-19 infection (mRS 0–2: 5/14 (35.7%) vs 15/94 (15.5%), p=0.076). In addition, the
mortality rate at discharge was lower in patients recovered from
COVID-19 compared with patients with acute COVID-19 infection,
but without statistical significance (mRS 6: 2/14 (14.3%) vs
31/94 (33%), p=0.16).
The pandemic and neurointervention

In a subgroup analysis, patients with severe acute COVID-19 infection with respiratory failure requiring intubation showed a significantly lower rate of functional independence with significantly higher mortality compared with patients with mild or moderate acute COVID-19 infection (mRS 0–2 at discharge: 0/30 (0%) vs 15/64 (23.4%), p=0.004; mRS 6 at discharge: 15/30 (50%) vs 16/64 (25%), p=0.016).

Univariate and multivariate analyses

We performed univariate and multivariate analyses to identify predictors for an unfavorable outcome (mRS 3–6) at discharge. In the univariate analysis, factors potentially associated with an unfavorable outcome were: no administration of IVT (p=0.001), ventilation (non-invasive or intubation due to respiratory failure, p<0.001), occlusion site in the ICA (p=0.041) or M1 (p=0.001), cardioembolic cause of AIS (p=0.075), higher pre-stroke mRS (p<0.001), tandem occlusion (p=0.021), lower ASPECTS at baseline (p=0.046) or after 24 hours (p=0.001), higher NIHSS at baseline (p=0.002) or at discharge (p<0.001), higher interval time between onset to groin puncture (p=0.042) and lower rates of mTICI 3 (p=0.026). After multicollinearity testing, administration of IVT, ventilation, cardioembolic cause of AIS, ASPECTS at baseline, NIHSS at baseline, interval time between onset to groin puncture and mTICI 3 rates were entered into a binary logistic regression analysis. Ventilation (OR 35.3, 95% CI 2.4 to 523.0; p=0.010) and interval time from onset to groin puncture (OR 1.02, 95% CI 1.00 to 1.04; p=0.016) remained as independent predictors for an unfavorable outcome.

DISCUSSION

We report a large series of patients with COVID-19 infection treated with MT due to LVO focusing on angiographic and clinical outcome. MT in patients with acute or subacute COVID-19 infection remains an infrequent event to date.

Recent studies have reported a prevalence rate of acute stroke in COVID-19 patients of 1.4–1.9%, including endovascular treatment due to LVO in about one of four patients (238/1223). These findings correspond with the low incidence and frequency rate of 1% in our study and might be due to several factors. First, our database included patients from 26 different stroke centers with its inherent heterogeneity in the respective populations. Other stroke patients with LVO and COVID-19 might have been admitted to other stroke centers in the various corresponding metropolitan areas. Second, MT in patients with acute severe COVID-19 infection could be complicated by diagnostic delays imposed by the fact that these patients are more likely to be sedated and intubated, thus impeding the early detection of neurological deterioration. Third, the COVID-19 pandemic compromised the application of well-established therapies and appears to be disruptive for acute stroke pathways. Stroke patients without respiratory symptoms of COVID-19 might not seek care at all, preferring to stay at home than taking the risk of getting exposed to SARS-CoV-2 at the hospital.

Our patient characteristics in terms of age (median age of 74), baseline NIHSS and ASPECTS are comparable with individual patient data meta-analysis on MT before the pandemic. In contrast, recent small-case series (n <15) have reported that patients with AIS with COVID-19 treated with MT were younger with median ages ranging from 39 to 59.5 years, had higher baseline NIHSS scores (median 17–27) and lower ASPECTS (median 5) at admission. It remains unclear whether the lower rate of young patients in our study (6.3% of patients aged <50 years)—in comparison to results of a recent systematic review which reported a corresponding rate of 17.4% of young patients with AIS with COVID-19—is underestimated due to patients preferring not to enter the hospital at all, as mentioned above.

Our retrospective analysis revealed several findings including high rates of successful and complete final reperfusion of up to 87% and 41%, respectively. The reperfusion rates are in line with recent analyses of MT in patients with COVID-19. In addition, the angiographic outcome is comparable to MT studies before the pandemic, suggesting that there is no distinction between MT being performed in an infected or non-infected patient with regard to technical feasibility, safety, and time to flow restoration.

This implies that thrombectomy in COVID-19 patients should be pursued with the same extensive effort as in non-infected patients, as these patients may achieve similar good angiographic outcomes. Otherwise, there is a high probability that mortality and functional independence would increase even more. Most importantly, our study showed the devastating outcome of patients with COVID-19 with AIS due to LVO, even though the reperfusion rates were high. Our results are consistent with another large European multicenter study of MT in COVID-19 patients (n=93) and meta-analyses of AIS patients with COVID-19 infection, which reported mortality rates ranging from 29% to 35%. The mortality is therefore twice as high as in the meta-analysis from HERMES (15%). Several aspects related to the COVID-19 infection may explain our findings, including the respiratory distress observed in some patients. Acute respiratory failure requiring non-invasive ventilation or intubation proved to be an independent factor for an unfavorable outcome in multivariate analysis. In fact, mortality was 50% in patients with acute respiratory failure due to COVID-19 infection undergoing MT and comparable to mortality data among COVID-19 patients with acute respiratory distress syndrome in national reports (all countries 39%). Besides, COVID-19 patients with stroke tend to have an elevated incidence of potentially fatal thrombotic complications that could have contributed to the increased risk of death. Indeed, we found a noticeably higher rate of re-occlusion within 30 days compared with a previous analysis of non-infected patients (4.5% vs 0.4%). Re-occlusions might be promoted by a prothrombotic state, antiphospholipid syndrome, cytokine storm or other coagulopathies—factors that have already been described with COVID-19 and related stroke pathogenesis.

Notably, patients with subisded COVID-19 infection tend to have a better clinical outcome than patients with acute COVID-19 infection. The mortality in this subgroup of our cohort corresponds to rates of mortality in non-infected stroke patients undergoing MT, indicating that recovered COVID-19 patients should be given separate consideration and stroke pathogenesis might be dissimilar to patients with acute SARS-CoV-2 infection.

Another important factor potentially negatively affecting the clinical outcome of infectious patients treated with MT due to LVO is the significant delay in performing thrombectomy. The median time interval from symptom onset to groin puncture in our study was higher than findings of the German Stroke Registry in 2019 (median 220 min vs 160 min). Additionally, the time interval from onset to groin puncture presented as an independent predictor for an unfavorable outcome in our multivariate analysis. Multiple studies have shown declines in the volumes of MT, IVT and stroke hospitalizations over the pandemic with delays in hospital arrival times and treatment workflow.

It is notable that 90% of thrombectomy procedures in our study were performed under general anesthesia. To date, there
are no current studies comparing the efficacy of general anesthesia and conscious sedation for MT in patients diagnosed with COVID-19. The decision to intubate for MT must be justified to the patient’s need for airway protection and the risk of aerosol exposure to the staff.

It remains unknown whether COVID-19 was primarily responsible for AIS in our study. Cardioembolic etiology for the LVO was found in most patients (38.7%) and could be potentially associated with the systemic hypercoagulability seen in patients with COVID-19. On the other hand, there is no indication of causality as the majority of patients had at least one known stroke risk factor.

An important limitation of our study is the retrospective and multicenter design including attendant selection bias and the use of different thrombectomy equipment and techniques although, notably, the reperfusion rates were high. Furthermore, our study is limited by the fact that the study did not consider a control group of non-infected patients.

CONCLUSIONS

Our study supports the fact that COVID-19 infection is associated with a devastating clinical outcome of patients with AIS due to LVO treated with MT. Patients with acute severe COVID-19 infection and respiratory failure tend to have the highest rate of mortality.

Author affiliations
1Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany
2Department of Radiology, Neuroradiology and Nuclear Medicine, University Medical Center Langendreer, Bochum, Germany
3Department of Diagnostic and Interventional Radiology, University Hospital Cologne, Cologne, Germany
4Department of Neurology and Center for Translational Neurosciences and Behavioral Sciences (CTNBS), University Hospital Essen, Essen, Germany
5Department of Neuroradiology, University of Heidelberg, Heidelberg, Germany
6Department of Neuroradiology, University of Erlangen-Nuremberg, Erlangen, Germany
7Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany
8Department of Neuroradiology, University Hospital Bonn, Bonn, Germany
9Institute and Polyclinic of Neuroradiology, Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany
10Department of Diagnostic and Interventional Radiology and Neuroradiology, Helios General Hospital Erfurt, Erfurt, Germany
11Department of Radiology and Neuroradiology, Klinikum Dortmund gGmbH, Dortmund, Germany
12Department of Neurology, Klinikum Dortmund gGmbH, Dortmund, Germany
13Department of Neuroradiology, University Hospital Magdeburg, Magdeburg, Germany
14Department of Radiology, University Hospital Magdeburg, Magdeburg, Germany
15Department of Diagnostic and Interventional Neuroradiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
16Department of Neuroradiology, Medical University of Innsbruck, Innsbruck, Austria
17Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
18Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
19Department of Diagnostic and Interventional Neuroradiology, University Hospital RWL (Campus Bethel), Bielefeld, Germany
20Department of Radiology and Neuroradiology, Klinikum Duisburg - Sana Kliniken, Duisburg, Germany
21Clinic for Neuroradiology, Klinikum Stuttgart, Stuttgart, Germany
22Institute of Neuroradiology, University Hospital Frankfurt and Goethe University, Frankfurt am Main, Germany
23Department of Radiology and Neuroradiology, Gemeinschaftskrankenhaus Herdecke, Herdecke, Germany
24Department of Neuroradiology, Klinikum Fulda, Fulda, Germany
25Department of Diagnostic and Interventional Neuroradiology, University Hospital Aachen, Aachen, Germany
26Department of Radiology, Klinikum Lueneburg, Lueneburg, Germany
27Department of Neuroradiology, Klinikum Fulda, Fulda, Germany
28Clinic for Radiology, University Hospital Muenster, Muenster, Germany
29Department of Neuroradiology, Vivantes Klinikum Neukoelln, Berlin, Germany
30Department of Diagnostic and Interventional Neuroradiology, University Hospital Aachen, Aachen, Germany
31Department of Neuroradiology, Alfried Krupp Hospital Ruettenscheid, Essen, Germany

Contributors
Guarantor: HS, Conception and design: CD, HS, Acquisition of data: HS, VM, MM, IM, FD, DK, DL, SR, MT, FE, ERG, TB-B, RK, MS-H, AK, RdMdr, JA, AR, AMD, CB, RM-M, BK, PS, AB, ON, PJM, Analysis and Interpretation of data: VM, LG, MK, CK, SF, BK, AL, MG, IK, GE, DB, LW, LM-S, IR, BB, DG, CA, J-US, VMS, CL, SR, US, YL, TR, AD, ME, MGS, MW, HH, RC, MF, CD, HS, Drafting the article: HS, LG.

Funding
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests
MM: Grants or contracts from Balt, Medtronic, MicroVention and Stryker. FD: Consultant for Balt, Cerus Endovascular, Phenox and Cerenvous, honoraria for lectures from Cerenvous, Acandis and Asahi, support for attending meetings from MicroVention, Acandis and Cerevascular, advisory board member for Cerenvous/Johnson & Johnson, associate editor for Journal of Neurointerventional Surgery. MG: Grants or contracts from Else Kröner Fresenius Stiftung, payment of honoraria for lectures from Phenox, procuring contract with MicroVention, participation on clinical event committee from MicroVention, chair of ESMINT Examination Committee, received stents from Phenox for research purposes. DK: Grants or contracts from Else Kröner Fresenius Center of Digital Health and Joachim Herz Foundation, spokesman of the "Junge Neuroradiologie" in the German Society of Neuroradiology. CL: Consulting fees, payment of honoraria for lectures and support for attending meetings from Phenox, Penumbra and Acadis. MW: Grants from ab medica, Acandis, Bracco Imaging, Cerenvous, Kaneka Pharmaceuticals, Medtronic, Mentice AB, Microvention, Phenox, Siemens Healthcare and Stryker Neurovascular; Consulting fees from Stryker Healthcare; Payment honoraria for lectures from Stryker Neurovascular. The other authors declare no specific conflict of interest.

Patient consent for publication
Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available upon reasonable request. Not applicable.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iDs
Volker Maus http://orcid.org/0000-0001-5097-2631
Lukas Goertz http://orcid.org/0000-0002-6260-7611
Daniel Kaiser http://orcid.org/0000-0001-5258-0025
Stefan Rohde http://orcid.org/0000-0002-6184-8617
Daniel Behme http://orcid.org/0000-0002-5353-9515
Fabian Flottmann http://orcid.org/0000-0001-8358-8089
Tobias Boech-Behrens http://orcid.org/0000-0003-0266-8947
Omid Nikoubashman http://orcid.org/0000-0002-2055-4217
Martin Wiesmann http://orcid.org/0000-0002-8261-5573
René Chapot http://orcid.org/0000-0002-2584-8361
Cornelius Deuschl http://orcid.org/0000-0001-9262-7289

REFERENCES
1. Mao L, Ji H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683–90.
2. Chou SH-Y, Beghi E, Helbok R, et al. Global incidence of neurological manifestations among patients hospitalized with COVID-19. A report for the GCS-NeuroCOVID Consortium and the ENERGy Consortium. JAMA Netw Open 2021;4:e211213.
The pandemic and neurointervention

3  Namroni S, de Groot R, Bell S, et al. Stroke in COVID-19: a systematic review and meta-analysis. Int J Stroke 2021;16:137–49.
4  Osley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 2020;382:e60.
5  Escalard S, Chalumeau V, Escalard C, et al. Early brain imaging shows increased severity of acute ischemic strokes with large vessel occlusion in COVID-19 patients. Stroke 2020;51:3366–70.
6  de Havenon A, Yaghi S, Mistry EA, et al. Endovascular thrombectomy in acute ischemic stroke patients with COVID-19: prevalence, demographics, and outcomes. J Neurointerv Surg 2020;12:1045–8.
7  Hesse DC, Eldadhan W, Rutkowski E. COVID-19-related stroke. Transl Stroke Res 2020;11:322–5.
8  Janardhan V, Janardhan V, Kalousek V. COVID-19 as a blood clotting disorder masquerading as a respiratory illness: a cerebrovascular perspective and therapeutic implications for stroke thrombectomy. J Neuroimaging 2020;30:555–61.
9  Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020;180:1081–9.
10 White TG, Martinez G, Wang J, et al. Impact of the COVID-19 pandemic on acute ischemic stroke presentation, treatment, and outcomes. Stroke Res Treat 2021;2021:1–8.
11 Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–29.
12 Friedman S, Bres Bunnich M, Jimenez-Ruiz A, et al. Stroke risk, phenotypes, and death in COVID-19: systematic review and newly reported cases. Neurology 2020;95:e3373–85.
13 Montaner J, Barragán-Prieto A, Pérez-Sánchez S, et al. Break in the stroke chain of survival due to COVID-19. Stroke 2020;51:2307–14.
14 Schirmer CM, Ringer AJ, Arthu AS, et al. Delayed presentation of acute ischemic strokes during the COVID-19 crisis. J Neurointerv Surg 2020;12:639–42.
15 Neves Briard J, Dufort G, Jacquin G, et al. Three-month functional outcomes following endovascular thrombectomy during the first wave of the COVID-19 pandemic: a Canadian single-center cohort study. J Neurointerv Surg 2022;14:274–9.
16 Goyal M, Menon BK, van Zwan WH, et al. Endovascular thrombectomy after large-vessel ischemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016;387:1723–31.
17 Cagnazzo F, Piotin M, Escalard S, et al. European multicenter study of ET-COVID-19. Stroke 2021;52:31–9.
18 Pop R, Hasiu A, Bolognini F, et al. Stroke thrombectomy in patients with COVID-19: initial experience in 13 cases. AJNR Am J Neuroradiol 2020;41:2012–6.
19 Escalard S, Maier B, Redjem H, et al. Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris. Stroke 2020;51:2540–3.
20 Hesse AC, Behme D, Kemmling A, et al. Comparing different thrombectomy techniques in five large-volume centers: a ‘real world’ observational study. J Neurointerv Surg 2018;10:525–9.
21 Maus V, Henkel S, Riabikin A, et al. The SAVE technique: large-scale experience for treatment of intracranial large vessel occlusions. Clin Neurol Neurosurg 2019;179:669–76.
22 Lapergue B, Blanc R, Gory B, et al. Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion: the ASTER randomized clinical trial. JAMA 2017;318:443–52.
23 Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med 2020;14:1149–63.
24 Styczyn H, Maegerlein C, Yeol LL, et al. Repeated mechanical thrombectomy in short-term large vessel occlusion recurrence: multicenter study and systematic review of the literature. J Neurointerv Surg 2020;12:neurintsurg-2020-015939–1193.
25 Valderrama EV, Humbert K, Lord A, et al. Severe acute respiratory syndrome coronavirus 2 infection and ischemic stroke. Stroke 2020;51:e124–7.
26 Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;75:2950–73.
27 Rohde S, Weber W, Berlis A, et al. Acute endovascular stroke treatment in Germany in 2019: results from a nationwide database. Clin Neurol Neurosurg 2021;191:1–19.
28 Noquist RG, Abdalkader M, Qureshi MM, et al. Global impact of COVID-19 on stroke care. Int J Stroke 2021;16:573–84.
29 Kerlouz F, Fabacher T, Bricout N, et al. Mechanical thrombectomy for acute ischemic stroke amid the COVID-19 outbreak: decreased activity, and increased care delays. Stroke 2020;51:2012–7.
30 Baracchini C, Pieroni A, Vario F, et al. Acute stroke management pathway during Coronavirus-19 pandemic. Neuroradiology 2020;41:1003–5.
ICMJE DISCLOSURE FORM

Date: 2/23/2022

Your Name: Franziska Dorn

Manuscript Title: Mechanical thrombectomy for acute ischemic stroke in COVID-19 patients: multicenter experience in 111 cases

Manuscript Number (If known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|
| **Time frame: Since the initial planning of the work** | |
| 1 | All support for the present manuscript [e.g., funding, provision of study materials, medical writing, article processing charges, etc.] No time limit for this item. | ☒ None |
| | | |
| | | |
| **Time frame: past 36 months** | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ☐ None |
| | Proctor/consultant for Balt, Cerus Endovascular, Phenox, Cerenovus | |
| | | |
| 3 | Royalties or licenses | ☒ None |
| | | |

1 12/13/2021
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 4 | Consulting fees                                                                                |                                                                                  |
|   | proctor/ consultant for Balt, Cereus Endovascular, Phenox, Cerenovus                           |                                                                                  |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events |                                                                                  |
|   | ☐ None                                                                                         |                                                                                  |
|   | Honoraria for lectures from Cerenovus, Acandis, Asahi                                            |                                                                                  |
| 6 | Payment for expert testimony                                                                    | ☒ None                                                                           |
| 7 | Support for attending meetings and/or travel                                                     | ☐ None                                                                           |
|   | Microvention, Acandis, Cereus Endovascular                                                      |                                                                                  |
| 8 | Patents planned, issued or pending                                                              | ☐ None                                                                           |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                               | ☐ None                                                                           |
|   | Advisory Board member for Cerenovus/Johnson&Johnson                                              |                                                                                  |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☐ None                                                                           |
|   | Associate Editor for JNIS                                                                       |                                                                                  |

ICMJE Disclosure Form

12/13/2021
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 11 | Stock or stock options                                                                        | ☑️ None                                                                           |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services              | ☑️ None                                                                           |
| 13 | Other financial or non-financial interests                                                    | ☑️ None                                                                           |

Please place an "X" next to the following statement to indicate your agreement:

☑️ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

[Signature]

Prof. Dr. med. Frankiska Domn
Stellvertretende Direktorin
Klinik für Neuroradiologie
Universitätsklinikum Bonn
Venusberg-Campus 1
65187 Bonn

31.2.2022

12/13/2021
ICMJE DISCLOSURE FORM

Date: 8/26/2021

Your Name: Matthias Gawlitza, MD

Manuscript Title: Mechanical thrombectomy for acute ischemic stroke in COVID-19 patients: multicenter experience in 111 cases

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Date of Disclosure | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Date: 8/26/2021    | ☒ None                                                                                   |                                                                                   |
|                    | All support for the present manuscript (e.g., funding, provision of study materials,    |                                                                                   |
|                    | medical writing, article processing charges, etc.)                                       |                                                                                   |
|                    | ☒ None                                                                                   |                                                                                   |
|                    | No time limit for this item.                                                             |                                                                                   |

Time frame: Since the initial planning of the work

| Date of Disclosure | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Date:              | ☐ None                                                                                   |                                                                                   |
|                    | Grants or contracts from any entity (if not indicated in item #1 above).                 |                                                                                   |
|                    | ☐ None                                                                                   |                                                                                   |
|                    | Else Kröner-Fresenius-Stiftung                                                            | Grant paid to the institution                                                     |

Time frame: past 36 months

| Date of Disclosure | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Date:              | ☒ None                                                                                   |                                                                                   |
|                    | Royalties or licenses                                                                     |                                                                                   |
|                    | ☒ None                                                                                   |                                                                                   |
|                    |                                                                                           |                                                                                   |
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 4 | Consulting fees                                                                                   | ☐ None                                                                          |
|   | MicroVention                                                                                      | Proctoring services                                                             |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☐ None                                                                          |
|   | Phenox                                                                                            | Lectures                                                                        |
| 6 | Payment for expert testimony                                                                      | ☒ None                                                                          |
| 7 | Support for attending meetings and/or travel                                                      | ☒ None                                                                          |
| 8 | Patents planned, issued or pending                                                                 | ☒ None                                                                          |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                                 | ☐ None                                                                          |
|   | Clinical Event Committee, MicroVention                                                            |                                                                                 |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☐ None                                                                          |
|   | ESMINT Examination Committee chair                                                                 | Unpaid                                                                          |
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 11 | Stock or stock options □ None                                                                  |                                                                                  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services □ None        |          Phenox                                                                 |
|    |                                                                                  | Stents provided for research purposes                                              |
| 13 | Other financial or non-financial interests □ None                                              |                                                                                  |

**Please place an “X” next to the following statement to indicate your agreement:**

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 1/11/2022

Your Name: Kaiser, Daniel

Manuscript Title: Mechanical thrombectomy for acute ischemic stroke in COVID-19 patients: multicenter experience in 111 cases

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Time frame: Since the initial planning of the work |
|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) |
| ☒ | None |

| Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|
|  |

| Time frame: past 36 months |
|---|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above) |
| ☐ | None |
| | Else Kröner Fresenius Center of Digital Health | Not related to the manuscript |
| | Joachim Herz Foundation | Not related to the manuscript |

| 3 | Royalties or licenses |
| ☒ | None |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 4 | Consulting fees                                                                                 | ☒ None                                                                           |
|   |                                                                                                  |                                                                                  |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ None                                                                           |
|   |                                                                                                  |                                                                                  |
| 6 | Payment for expert testimony                                                                     | ☒ None                                                                           |
|   |                                                                                                  |                                                                                  |
| 7 | Support for attending meetings and/or travel                                                     | ☒ None                                                                           |
|   |                                                                                                  |                                                                                  |
| 8 | Patents planned, issued or pending                                                               | ☒ None                                                                           |
|   |                                                                                                  |                                                                                  |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                                | ☒ None                                                                           |
|   |                                                                                                  |                                                                                  |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☐ None, spokesman of the “Junge Neuroradiologie” in the German Society of Neuroradiology | Not related to the manuscript                                                  |
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 11 | **Stock or stock options** □ None                                                                |                                                                                  |
| 12 | **Receipt of equipment, materials, drugs, medical writing, gifts or other services** □ None     |                                                                                  |
| 13 | **Other financial or non-financial interests** □ None                                           |                                                                                  |

Please place an “X” next to the following statement to indicate your agreement:

☐ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 2/13/2022

Your Name: Christian Loehr

Manuscript Title: Mechanical thrombectomy for acute ischemic stroke in COVID-19 patients: multicenter experience in 111 cases

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Time frame: Since the initial planning of the work |
| Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| --- | --- |
| ☒ None | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) |
| | No time limit for this item |
| Time frame: past 36 months |

| Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| --- | --- |
| ☐ None | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). |
| | |
| ☐ None | |
| 3 | Royalties or licenses |
| | |
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 4 | Consulting fees                                                                         | ☒ None                                                                             |
|   | Phenox                                                                                  |                                                                                  |
|   | Penumbra                                                                                |                                                                                  |
|   | Acandis                                                                                 |                                                                                  |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ None                                                                             |
|   | Phenox                                                                                  |                                                                                  |
|   | Penumbra                                                                                |                                                                                  |
|   | Acandis                                                                                 |                                                                                  |
| 6 | Payment for expert testimony                                                            | ☐ None                                                                             |
| 7 | Support for attending meetings and/or travel                                            | ☒ None                                                                             |
|   | Phenox                                                                                  |                                                                                  |
|   | Penumbra                                                                                |                                                                                  |
|   | Acandis                                                                                 |                                                                                  |
| 8 | Patents planned, issued or pending                                                       | ☐ None                                                                             |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                        | ☐ None                                                                             |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☐ None                                                                             |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| 11 | Stock or stock options | ☐ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☐ None |
| 13 | Other financial or non-financial interests | ☒ None |

Please place an “X” next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 1/12/2022

Your Name: Markus A Möhlenbruch

Manuscript Title: Mechanical thrombectomy for acute ischemic stroke in COVID-19 patients: multicenter experience in 111 cases

Manuscript Number (if known): [Click or tap here to enter text]

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Time frame: Since the initial planning of the work |
| Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | ☒ None |
| No time limit for this item. | |

| Time frame: past 36 months |
| Grants or contracts from any entity (if not indicated in item #1 above). | ☐ None |
| Balt | Paid to the institution |
| Medtronic | Paid to the institution |
| MicroVention | Paid to the institution |
| Stryker | Paid to the institution |

| Royalties or licenses | ☒ None |
| | | | |

Styczen H, et al. J NeuroIntervent Surg 2022;0:1–6. doi: 10.1136/neurintsurg-2022-018723
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 4 | Consulting fees ☒ None |                                                                                   |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events ☒ None |                                                                                   |
| 6 | Payment for expert testimony ☒ None |                                                                                   |
| 7 | Support for attending meetings and/or travel ☒ None |                                                                                   |
| 8 | Patents planned, issued or pending ☒ None |                                                                                   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board ☒ None |                                                               |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid ☒ None |                                                                                   |
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 11 | Stock or stock options | ☒ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☒ None |
| 13 | Other financial or non-financial interests | ☒ None |

Please place an “X” next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: 1/21/2022

Your Name: Martin Wiesmann

Manuscript Title: Mechanical thrombectomy for acute ischemic stroke in COVID-19 patients: multicenter experience in 111 cases

Manuscript Number (if known): [Click or tap here to enter text.]

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Time frame: Since the initial planning of the work |
|-----------------------------------------------|
| Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | ☒ None |
| | No time limit for this item. | |
| | | |

| Time frame: past 36 months |
|-----------------------------|
| Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ☒ None |
| | jab medica | Payments to institution |
| | Acandis | Payments to institution |
| | Bracco Imaging | Payments to institution |
| | Cerenovus | Payments to institution |
| | Kaneka Pharmaceuticals | Payments to institution |
| | Medtronic | Payments to institution |
| | Mentice AB | Payments to institution |
| | Microvention | Payments to institution |
| | Phenox | Payments to institution |
| | Siemens Healthcare | Payments to institution |
| | Stryker Neurovascular | Payments to institution |
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 3 | Royalties or licenses                                                                                                           | ☒ None                                                                                     |
|   |                                                                                                                                   |                                                                                       |
| 4 | Consulting fees                                                                                                                  | ☒ None                                                                                     |
|   | Stryker Healthcare                                                                                                               | Payments to me                                                                             |
|   |                                                                                                                                   |                                                                                       |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events                      | ☐ None                                                                                     |
|   | Stryker Neurovascular                                                                                                           | Payments to me                                                                             |
|   |                                                                                                                                   |                                                                                       |
| 6 | Payment for expert testimony                                                                                                     | ☒ None                                                                                     |
|   |                                                                                                                                   |                                                                                       |
| 7 | Support for attending meetings and/or travel                                                                                     | ☒ None                                                                                     |
|   |                                                                                                                                   |                                                                                       |
| 8 | Patents planned, issued or pending                                                                                                | ☒ None                                                                                     |
|   |                                                                                                                                   |                                                                                       |
| 9 | Participation on a Data Safety                                                                                                   | ☒ None                                                                                     |
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☒ None                                                                 |
| 11 | Stock or stock options                                                                       | ☒ None                                                                 |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services               | ☒ None                                                                 |
| 13 | Other financial or non-financial interests                                                    | ☒ None                                                                 |

Please place an “X” next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.